Iridaceae ve Cimicifuga racemosadan elde edilen ekstrelerin ve tectorigeninin hiçbir uterotropik etkiye sahip olmayan bir estrojen-tipi, organ-seçiçi ilaç olarak kullanımı

• Main Authors: WOLFGANG WUTTKE, MICHAEL POPP, VOLKER CHRISTOFFEL, BARBARA SPENGLER, HUBERTUS JARRY
• Format: Patent
• Language: Turkish
• Published: 21.12.2000
• Edition: 7
• Subjects: ARRANGEMENTS FOR MEASURING TWO OR MORE VARIABLES NOT COVEREDIN A SINGLE OTHER SUBCLASS; HUMAN NECESSITIES; HYGIENE; MEASURING; MEASURING NOT SPECIALLY ADAPTED FOR A SPECIFIC VARIABLE; MEASURING OR TESTING NOT OTHERWISE PROVIDED FOR; MEDICAL OR VETERINARY SCIENCE; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; TARIFF METERING APPARATUS; TESTING

Mevcut bulus, Iridaceae ve Cimicifuga racemosadan elde edilen ekstrelerin ve tectorigeninin, kalp damar hastaliklarinin, özellikle ateroskleroz, osteoporoz ve degisim bozukluklarinin, örnegin ates basmalarinin önlenmesi veya hafifletilmesi gibi seçici tedavisi ve/veya önlenmesi için bir estrojen-tipi organ-seçiçi ilaç olarak kullanimi ile ilgilidir. Pratik olarak uterotrofik etkiler gözlenmemektedir. The invention relates to the utilization of extracts from iris plants, cimicifuga racemosa and tectorigenin as an estrogen-like organ-selective medicament for selectively treating and/or for the prophylaxis of cardiovascular diseases, especially arteriolosclerosis, osteoporosis and climacteric symptoms, for example, for preventing or alleviating hot flashes. Virtually no uterotropic effects are observed when using said abstracts.